AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20586522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18852414 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT treatment followed by PDT
Number of subjects: 84
Study 18852414 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 84
Study 17058733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-liter electrolyte lavage solution plus 20 mg of oral bisacodyl
Number of subjects: 300
Study 17058733 — intervention group
Group type: COMPARATOR
Intervention: 4 liters of electrolyte lavage
Number of subjects: 300
Study 12656935 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (sodium valproate and valproic acid)
Number of subjects: 38
Study 12656935 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 38
Study 10690133 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 1.5 mg kg‐1
Number of subjects: 56
Study 10690133 — intervention group
Group type: COMPARATOR
Intervention: vecuronium 0.1 mg kg‐1
Number of subjects: 56
Study 10690133 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 56
Study 8739020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 0.5 mg
Number of subjects: 12
Study 8739020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 1.0 mg and higher
Number of subjects: 12
Study 8739020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat
Number of subjects: 12
Study 8739020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 2.5 mg
Number of subjects: 12
Study 8739020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 10 mg
Number of subjects: 12
Study 8739020 — intervention group
Group type: COMPARATOR
Intervention: Oral quinapril 20 mg
Number of subjects: 12
Study 8739020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat 10 mg and oral quinapril 20 mg
Number of subjects: 12
Study 8739020 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 12
Study 1763919 — intervention group
Group type: EXPERIMENTAL
Intervention: Starr‐Edwards prosthesis (Group A)
Number of subjects: 236
Study 1763919 — intervention group
Group type: COMPARATOR
Intervention: Saint Jude prosthesis (Group B)
Number of subjects: 236
Study 6352533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tolnaftate cream
Number of subjects: 97
Study 6352533 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% undecylenic acid and its zinc salt cream
Number of subjects: 97
Study 6352533 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 97
Study 30015785 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐ and Family‐focused Cognitive‐Behavioral Therapy (CFF‐CBT)
Number of subjects: 71
Study 30015785 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 71
Study 28112799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine (0.6 g per day for 8 weeks)
Number of subjects: 67
Study 28112799 — intervention group
Group type: COMPARATOR
Intervention: Acitretin (0.75 mg kg‐1 per day from week 0 to week 2 and 20‐30 mg per day from week 3 to week 8)
Number of subjects: 67
Study 26577964 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 140
Study 26577964 — intervention group
Group type: COMPARATOR
Intervention: Clipping
Number of subjects: 140
Study 22257685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 2569
Study 22257685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2569
Study 21743374 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (as needed basis)
Number of subjects: 45
Study 21743374 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype (PMs and UMs)
Number of subjects: 45
Study 18398801 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with atypical antipsychotics (AAP), particularly olanzapine; specific dosage and duration not mentioned.
Number of subjects: 0
Study 18398801 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with atypical antipsychotics (AAP); specific dosage and duration not mentioned.
Number of subjects: 0
Study 16547993 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional sonography (3D US)
Number of subjects: 35
Study 16547993 — intervention group
Group type: COMPARATOR
Intervention: Cholescintigraphy
Number of subjects: 35
Study 12663011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin 0.3%
Number of subjects: 18
Study 12663011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3%
Number of subjects: 18
Study 12663011 — intervention group
Group type: COMPARATOR
Intervention: Comparison of aqueous humor concentrations of ciprofloxacin and ofloxacin
Number of subjects: 18
Study 12663011 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intravitreal concentrations of ciprofloxacin and ofloxacin
Number of subjects: 18
Study 11400186 — intervention group
Group type: COMPARATOR
Intervention: (R)‐carvedilol 12.5 mg
Number of subjects: 12
Study 11400186 — intervention group
Group type: COMPARATOR
Intervention: (S)‐carvedilol 12.5 mg
Number of subjects: 12
Study 11400186 — intervention group
Group type: COMPARATOR
Intervention: (R,S)‐carvedilol 25 mg
Number of subjects: 12
Study 11400186 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 12
Study 9257784 — intervention group
Group type: EXPERIMENTAL
Intervention: mSRW (mean, 23.8 microg of Amb a 1)
Number of subjects: 21
Study 9257784 — intervention group
Group type: EXPERIMENTAL
Intervention: mSRW
Number of subjects: 21
Study 9257784 — intervention group
Group type: EXPERIMENTAL
Intervention: mSRW (high doses >20 microg of Amb a 1)
Number of subjects: 21
Study 9257784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8292063 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dimetindene
Number of subjects: 12
Study 8292063 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dimetindene
Number of subjects: 12
Study 8292063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3487668 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective distal splenorenal shunt (DSRS)
Number of subjects: 0
Study 3487668 — intervention group
Group type: COMPARATOR
Intervention: Total shunt (H-graft interposition total shunt)
Number of subjects: 0
Study 30572458 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert proctoring
Number of subjects: 45
Study 30572458 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 45
Study 30572458 — intervention group
Group type: COMPARATOR
Intervention: Independent training
Number of subjects: 45
Study 27591093 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy individuals
Number of subjects: 36
Study 27591093 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with unilateral ZMC fracture
Number of subjects: 36
Study 24944136 — intervention group
Group type: EXPERIMENTAL
Intervention: Street football training (FG)
Number of subjects: 22
Study 24944136 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 22
Study 23991622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (30 mg loading dose before angiography, additional 30 mg at PCI if indicated)
Number of subjects: 4033
Study 23991622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (pretreatment)
Number of subjects: 4033
Study 23991622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 4033
Study 21414048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with gradual updosing to 800 mg of protein (5 peanuts/day) followed by 30-week maintenance
Number of subjects: 22
Study 21414048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with gradual updosing
Number of subjects: 22
Study 21414048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 22
Study 18806534 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fentanyl plus dexpanthenol
Number of subjects: 40
Study 18806534 — intervention group
Group type: COMPARATOR
Intervention: Dexpanthenol
Number of subjects: 40
Study 16814058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring (ISCR) in Group 1 (179 patients)
Number of subjects: 280
Study 16814058 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2, 101 patients without ISCR)
Number of subjects: 280
Study 12882850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Lifestyle Program (MLP)
Number of subjects: 279
Study 12882850 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 279
Study 10995003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (1.5 g/m2, 2.25 g/m2, or 3 g/m2 every 2 weeks for three doses)
Number of subjects: 25
Study 10995003 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine (25 mg/m2/day for 5 days every 4 weeks for six cycles)
Number of subjects: 25
Study 10995003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 25
Study 10995003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine followed by high-dose cyclophosphamide
Number of subjects: 25
Study 8630632 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg once daily
Number of subjects: 379
Study 8630632 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg daily
Number of subjects: 379
Study 1467811 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.5 mg i.v.)
Number of subjects: 64
Study 3849459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatin
Number of subjects: 8
Study 3849459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 8
Study 3849459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pancreatin and Cimetidine
Number of subjects: 8
Study 3849459 — intervention group
Group type: COMPARATOR
Intervention: No treatment (previous studies)
Number of subjects: 8
Study 3849459 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (previous studies)
Number of subjects: 8
Study 31875756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 46
Study 31875756 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 46
Study 31875756 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 46
Study 31875756 — intervention group
Group type: COMPARATOR
Intervention: All groups (Dexmedetomidine, Propofol, Midazolam)
Number of subjects: 46
Study 30388128 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with low‐educated mothers
Number of subjects: 2513
Study 30388128 — intervention group
Group type: COMPARATOR
Intervention: Infants with high‐educated mothers
Number of subjects: 2513
Study 27185505 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-lingual breastfeeding education on a touch screen computer program
Number of subjects: 46
Study 27185505 — intervention group
Group type: COMPARATOR
Intervention: Printed educational material (Control)
Number of subjects: 46
Study 24752311 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 209
Study 24752311 — intervention group
Group type: COMPARATOR
Intervention: repaglinide
Number of subjects: 209
Study 21741883 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 290
Study 21741883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 290
Study 21741883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 19942263 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator training for prostate biopsy collection emphasizing core length and number of cores obtained.
Number of subjects: 4649
Study 19942263 — intervention group
Group type: COMPARATOR
Intervention: Entry biopsies (before investigator training).
Number of subjects: 4649
Study 19029215 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivocaine
Number of subjects: 48
Study 19029215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17012980 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive quetiapine (<400 mg/day)
Number of subjects: 102
Study 17012980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 14656032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy
Number of subjects: 50
Study 14656032 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin therapy
Number of subjects: 50
Study 11303312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with nephrotic syndrome (subgroup I/A)
Number of subjects: 57
Study 11303312 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 57
Study 8965152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 12
Study 8965152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (APAP/C)
Number of subjects: 12
Study 8965152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1464159 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment during intensive consolidation
Number of subjects: 224
Study 1464159 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate (F) levels during treatment
Number of subjects: 224
Study 1464159 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival correlation with RBC MTX levels
Number of subjects: 224
Study 1464159 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC MTX and RBC F levels during maintenance therapy
Number of subjects: 224
Study 6144241 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 16
Study 6144241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31738483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-target group (LDL cholesterol < 70 mg/dL)
Number of subjects: 2860
Study 31738483 — intervention group
Group type: COMPARATOR
Intervention: Higher-target group (LDL cholesterol 90-110 mg/dL)
Number of subjects: 2860
Study 30763799 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depression subtype
Number of subjects: 375
Study 30763799 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate depression with anxiety subtype
Number of subjects: 375
Study 30763799 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild depression with anxiety/somatization subtype
Number of subjects: 375
Study 28150964 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of CACR
Number of subjects: 98
Study 28150964 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of CACR
Number of subjects: 98
Study 26084138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1.5 mg/kg loading dose and patient-controlled analgesia for 1 day)
Number of subjects: 0
Study 26084138 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1 g intravenously 30 min before the end of the operation and 1 g each day at 6‐h intervals)
Number of subjects: 0
Study 23144370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tension group (n = 44)
Number of subjects: 90
Study 23144370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tension group (n = 46)
Number of subjects: 90
Study 23144370 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 60)
Number of subjects: 90
Study 21527040 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 6
Study 18632258 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol (400 mcg and 24 mcg/day, respectively)
Number of subjects: 0
Study 18632258 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (800 mcg/day)
Number of subjects: 0
Study 16926575 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender point examination (TP) in women with VVS
Number of subjects: 16
Study 16926575 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonaffected women)
Number of subjects: 16
Study 16926575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain history and interference assessments in women with VVS
Number of subjects: 16
Study 16926575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain behaviors in women with VVS
Number of subjects: 16
Study 14620469 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body cooling (UC)
Number of subjects: 16
Study 14620469 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body cooling combined with leg heating (UCLH)
Number of subjects: 16
Study 14620469 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 11125148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor physostigmine
Number of subjects: 0
Study 9013229 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to protocol
Number of subjects: 148
Study 1575333 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg and 1.0 mg/kg 3 min later)
Number of subjects: 12
Study 1575333 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5.0 mg/kg and 2.0 mg/kg 3 min later)
Number of subjects: 12
Study 1575333 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 12
Study 1575333 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 12
Study 3976960 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributable benefit or risk information
Number of subjects: 318
Study 3976960 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk information
Number of subjects: 318
Study 3976960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no data)
Number of subjects: 318
Study 31939265 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) applied perineally, 3000 pulses weekly for four consecutive weeks, energy flux density 0.25 mJ/mm2, frequency 4 Hz
Number of subjects: 62
Study 31939265 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with a non-functional handpiece
Number of subjects: 62
Study 29530260 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval Cues (RCs) presented during exposure
Number of subjects: 65
Study 29530260 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval Cues (RCs) perceived as comforting (safety signals)
Number of subjects: 65
Study 29530260 — intervention group
Group type: COMPARATOR
Intervention: No Retrieval Cues (Control group)
Number of subjects: 65
Study 27526146 — intervention group
Group type: EXPERIMENTAL
Intervention: BioPQQ™ (20 mg)
Number of subjects: 20
Study 27526146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25645368 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient report
Number of subjects: 756
Study 25645368 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician report
Number of subjects: 756
Study 24429126 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol 110 μg and glycopyrronium 50 μg)
Number of subjects: 2224
Study 24429126 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium (50 μg)
Number of subjects: 2224
Study 24429126 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (18 μg)
Number of subjects: 2224
Study 21905970 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 0
Study 21905970 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 0
Study 21905970 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Number of subjects: 0
Study 21905970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21905970 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg and 90 mg
Number of subjects: 0
Study 19011432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 57
Study 19011432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16870690 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12055461 — intervention group
Group type: EXPERIMENTAL
Intervention: No retinopexy (group 1)
Number of subjects: 60
Study 12055461 — intervention group
Group type: COMPARATOR
Intervention: Transscleral cryotherapy (group 2)
Number of subjects: 60
Study 10598700 — intervention group
Group type: COMPARATOR
Intervention: Standard valve, siphon-reducing valve (Delta), flow-limiting valve (Orbis Sigma)
Number of subjects: 344
Study 10598700 — intervention group
Group type: COMPARATOR
Intervention: Frontal horn catheter tip location
Number of subjects: 344
Study 10598700 — intervention group
Group type: COMPARATOR
Intervention: Occipital horn catheter tip location
Number of subjects: 344
Study 10598700 — intervention group
Group type: COMPARATOR
Intervention: Ventricular catheter tips surrounded by cerebrospinal fluid
Number of subjects: 344
Study 10598700 — intervention group
Group type: COMPARATOR
Intervention: Ventricular catheter tips touching the brain
Number of subjects: 344
Study 10598700 — intervention group
Group type: COMPARATOR
Intervention: Patients with myelomeningocele
Number of subjects: 344
Study 10598700 — intervention group
Group type: COMPARATOR
Intervention: Patients with large ventricles
Number of subjects: 344
Study 8550958 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMDEX diagnostic interview
Number of subjects: 1173
Study 8550958 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMDEX criteria
Number of subjects: 1173
Study 8550958 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic interview
Number of subjects: 1173
Study 8550958 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for major depressive disorder
Number of subjects: 1173
Study 1743317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1‐mg Estraderm Patch worn for 7 days with 0.6 mL of ethanol injected on day 3
Number of subjects: 8
Study 1743317 — intervention group
Group type: COMPARATOR
Intervention: 0.1‐mg Estraderm Patch worn for 7 days without ethanol
Number of subjects: 8
Study 6292957 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin ophthalmic solution
Number of subjects: 40
Study 6292957 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic solution
Number of subjects: 40
Study 31928864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS (10Hz, 250 pulse) - single treatment
Number of subjects: 72